Adgero Biopharmaceuticals Holdings Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

 


Get this Report



PayPal Verified Vendor

Rating

4.2 Star Rating for report Adgero Biopharmaceuticals Holdings Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
4.2 / 5 stars rating
Pages: 34
Price: $250.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Adgero Biopharmaceuticals Holdings Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
 

Description

Adgero Biopharmaceuticals Holdings Inc (Adgero) is a biopharmaceutical company which advances its proprietary late stage photodynamic therapy (PDT) for the treatment of unmet clinical needs of patients with cutaneous metastatic breast cancer (CMBC) and bile duct cancer. Its PDT is a treatment utilizes light sensitive compounds which act as catalyst to produce a form of oxygen that induces local tumor cell death when exposed to specific wavelengths of light. The company's lead pipeline candidate, REM-001 therapy, consists of a light delivery device; a laser light source, and the drug REM-001. It is also investigating REM-001 as follow on indication for Cutaneous Metastatic Cancers of Lung, Colon, and Ovary. Adgero is headquartered in Princeton Junction, New Jersey, the US. 

Report Source Information

Supplied by: Research and Experts 
Date Published: 2017-11-27 

Report: Adgero Biopharmaceuticals Holdings Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

 

Contents

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Adgero Biopharma Acquires Certain Assets and Regulatory Filings from Miravant Medical Technologies 10
Venture Financing 11
Adgero Biopharma Raises USD0.5 Million in Venture Financing 11
Adgero Biopharma Raises USD3 Million Financing 12
Adgero Biopharma Raises Funds through Venture Financing 13
Equity Offering 14
Adgero Biopharma Raises USD3.4 Million in Private Placement of Shares upon Exercise of Warrants 14
Adgero Biopharma Raises USD2 Million in Equity Financing 15
Adgero Biopharma to Raise Funds in Private Placement of Shares and Warrants 16
Adgero Biopharma Raises USD2 Million in Private Placement of Shares 17
Adgero Biopharma Raises USD9.7 Million in Equity Financing 18
Debt Offering 19
Adgero Biopharma Raises USD0.3 Million in Private Placement of 6% Notes Due 2016 19
Adgero Biopharma Raises Funds in Private Placement of 6% Notes Due 2016 20
Adgero Biopharma Raises Funds in Private Placement of 6% Notes Due 2016 21
Adgero Biopharmaceuticals Holdings Inc - Key Competitors 22
Adgero Biopharmaceuticals Holdings Inc - Key Employees 23
Adgero Biopharmaceuticals Holdings Inc - Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Corporate Communications 25
Oct 25, 2017: Adgero Biopharmaceuticals Appoints John Liatos as Chief Financial Officer 25
Sep 14, 2017: Adgero Biopharmaceuticals Appoints Felix T. Garzon, M.D., Ph.D. as Chief Medical Officer 26
Feb 14, 2017: Adgero Biopharmaceuticals Holdings, Inc. Expands Executive Management Team with Appointment of Jane M. Maida as Chief Financial Officer 27
Product News 28
09/27/2016: Adgero Biopharmaceuticals to Present at the Fifth Annual OktoberINVESTfest, US - Bavaria, Germany Investors Conference in New York 28
05/03/2016: Adgero Biopharmaceuticals to Present at the Joseph Gunnar Pioneers 2016 Conference 29
01/26/2017: Adgero Biopharmaceuticals to Present at Noble Capital Markets' Thirteenth Annual Investor Conference 30
01/14/2016: Adgero Biopharmaceuticals to Present at Noble Financial Capital Markets 12th Annual Investor Conference on January 18, 2016 31
01/05/2016: Adgero Biopharmaceuticals to Present at Biotech Showcase on January 11, 2016 32
Clinical Trials 33
Apr 10, 2017: Positive Clinical Data of Adgero Biopharmaceuticals' REM-001 Therapy for the Treatment of Cutaneous Metastatic Breast Cancer Presented at 37th ASLMS Annual Conference 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34
 

List of Tables

List of Tables
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Key Facts 2
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Adgero Biopharmaceuticals Holdings Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Adgero Biopharma Acquires Certain Assets and Regulatory Filings from Miravant Medical Technologies 10
Adgero Biopharma Raises USD0.5 Million in Venture Financing 11
Adgero Biopharma Raises USD3 Million Financing 12
Adgero Biopharma Raises Funds through Venture Financing 13
Adgero Biopharma Raises USD3.4 Million in Private Placement of Shares upon Exercise of Warrants 14
Adgero Biopharma Raises USD2 Million in Equity Financing 15
Adgero Biopharma to Raise Funds in Private Placement of Shares and Warrants 16
Adgero Biopharma Raises USD2 Million in Private Placement of Shares 17
Adgero Biopharma Raises USD9.7 Million in Equity Financing 18
Adgero Biopharma Raises USD0.3 Million in Private Placement of 6% Notes Due 2016 19
Adgero Biopharma Raises Funds in Private Placement of 6% Notes Due 2016 20
Adgero Biopharma Raises Funds in Private Placement of 6% Notes Due 2016 21
Adgero Biopharmaceuticals Holdings Inc, Key Competitors 22
Adgero Biopharmaceuticals Holdings Inc, Key Employees 23
 

List of Figures

List of Figures
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Adgero Biopharmaceuticals Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
 

Scope


- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

 

Classification

Language Code: EN 
Region: United States 
Report Type: Company Reports 
Industry: Life Sciences 
Sector: Life Sciences 
Pages: 34 

Reasons to buy this report

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
 

Adgero Biopharmaceuticals Holdings Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Report 05IC-GDPH2521720D has a rating of 84 percent
Figure of merit assessment for report 05IC-GDPH2521720D

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1555

Taxonomy Location

The taxonomy on the left shows the ancestors of the United States node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

United States

The US has the largest economy in the world. It is highly industrialised and some of the main industries include; petroleum, steel, motor vehicles, aerospace, telecommunications, chemicals, electronics, food processing, consumer goods, lumber and mining.  

The US economy is dealing with slow growth rates, unemployment and increasing national debt since the recession of 2008/2009 however economists expect much higher growth in the US economy in 2014. The IMF expects growth to increase from 1.9% in 2013 to 2.8% in 2014.  The IMF expects a drop in unemployment to 6% in 2014. The indicators are good. The private sector is growing, federal spending will continue and some of the underlying drags on the economy are diminishing. Cheaper energy coming from increased oil exploration, gas fracking and renewables has helped to bring more jobs back to the US. The manufacturing sector is growing again and manufacturing technology is improving. 

There is a shortage of housing as a result of limited construction in recent years. Satisfying this demand should provide a much needed boost for the construction industry. There has also been considerable under investment in many other areas of the economy during the credit crunch and it is expected that there will be growth in the IT sector as companies carry out much needed upgrading of systems. 

Inequality is a major issue in the US economy. More of the wealth is going to the top 1% of high earners and middle incomes are stagnant. Tax reform is necessary for the redistribution of wealth. By putting more money in the pockets of the lower and middle classes the US economy will start to see some real growth.

Researchandexperts.com is a leading source of market research on key industry sectors in the USA.

Useful Links

World Bank Overview of the United States

CIA World Factbook on the United States

The International Monetary Fund on the US Economy

United States

Northern America

Region

 

North America

The term North America usually refers to the US and Canada sometimes including Geenland, Mexico and the islands of Bermuda, St Helena and Saint Pierre et Miquelon.  

North America is dominated by the largest global economy, the United States. The main industries in the US are technology, petroleum, steel, motor vehicles, aerospace, telecommunications, chemicals, electronics, food processing, consumer goods, lumber and mining. The US main tading partners are Canada, China, Mexico, Japan, and Germany. Canada is one of the largest economies in the world and is listed as one of the G8. Canada has a well established services sector along with well established industries in the areas of maufacturing, mining and logging. Canada's main trading partners are US, EU, China and Mexico.

 Research and Experts, the market intelligence platform, provides companies with access to the latest leading industry reports covering the North American region. Our company reports contain the following information; company overviews, key facts, key employees, products and services, as well as financial ratios. Our industry reports are vital sources of detailed historic and forecast values for markets in North America, segmented at category level.

Research and Experts reports also provide regional analysis and analysis of the leading companies in key North American markets.  Researchandexperts.com is a  leading source of market research on North America.

North America

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 205

Taxonomy Location

The taxonomy on the left shows the ancestors of the Life Sciences node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Adgero Biopharmaceuticals Holdings Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

 

Item Code: 05IC-GDPH2521720D

 
Licence: Single User
Price: $250.00
 
VAT: 0.0% 
Total: $250.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [1.46375s]

--